Answer
Cangrelor (Kengrexal) selectively and reversibly binds to the platelet P2Y12 receptor, blocking ADP-induced platelet activation and aggregation.
Sources for this answer
- Kengrexal 50 mg powder for concentrate for solution for injection / infusion.Chiesi Limited · emc · SmPC §5.1 Pharmacodynamic properties · Version 8Document updated
Sources checked